메뉴 건너뛰기




Volumn 11, Issue 11, 2009, Pages 1071-1077

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

Author keywords

Anaemia; Haemoglobin; Heart failure; Kidney; Mortality

Indexed keywords

CREATININE; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; TRANSFERRIN;

EID: 71049164279     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp130     Document Type: Article
Times cited : (28)

References (43)
  • 2
    • 17844403494 scopus 로고    scopus 로고
    • Prevalence of anemia and effects on mortality in patients with heart failure.
    • Lindenfeld J. Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 2005;149:391-401.
    • (2005) Am Heart J , vol.149 , pp. 391-401
    • Lindenfeld, J.1
  • 4
    • 0037024202 scopus 로고    scopus 로고
    • Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.
    • Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-1786.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 1780-1786
    • Horwich, T.B.1    Fonarow, G.C.2    Hamilton, M.A.3    MacLellan, W.R.4    Borenstein, J.5
  • 12
    • 0036296978 scopus 로고    scopus 로고
    • Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study.
    • McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-1936.
    • (2002) J Am Soc Nephrol , vol.13 , pp. 1928-1936
    • McClellan, W.M.1    Flanders, W.D.2    Langston, R.D.3    Jurkovitz, C.4    Presley, R.5
  • 13
    • 0037458127 scopus 로고    scopus 로고
    • Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure.
    • Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294-299.
    • (2003) Circulation , vol.107 , pp. 294-299
    • Mancini, D.M.1    Katz, S.D.2    Lang, C.C.3    Lamanca, J.4    Hudaihed, A.5    Androne, A.S.6
  • 14
    • 33845216454 scopus 로고    scopus 로고
    • Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    • Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabro A, Campagna SM, Nuti R. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152: 1096. e1099-1015.
    • (2006) Am Heart J , vol.152-1096
    • Palazzuoli, A.1    Silverberg, D.2    Iovine, F.3    Capobianco, S.4    Giannotti, G.5    Calabro, A.6    Campagna, S.M.7    Nuti, R.8
  • 18
    • 34548798205 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia
    • DOI 10.1093/eurheartj/ehm328
    • van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208-2216. (Pubitemid 47428946)
    • (2007) European Heart Journal , vol.28 , Issue.18 , pp. 2208-2216
    • Van Veldhuisen, D.J.1    Dickstein, K.2    Cohen-Solal, A.3    Lok, D.J.A.4    Wasserman, S.M.5    Baker, N.6    Rosser, D.7    Cleland, J.G.F.8    Ponikowski, P.9
  • 21
    • 33846669860 scopus 로고    scopus 로고
    • Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with ery-thropoietin: A meta-analysis.
    • Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with ery-thropoietin: a meta-analysis. Lancet 2007;369:381-388.
    • (2007) Lancet , vol.369 , pp. 381-388
    • Phrommintikul, A.1    Haas, S.J.2    Elsik, M.3    Krum, H.4
  • 23
    • 0025913812 scopus 로고
    • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
    • The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
    • (1991) N Engl J Med , vol.325 , pp. 293-302
  • 24
    • 0033514046 scopus 로고    scopus 로고
    • The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial.
    • The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
    • (1999) Lancet , vol.353 , pp. 9-13
  • 25
    • 0033549290 scopus 로고    scopus 로고
    • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).
    • Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353: 2001-2007.
    • (1999) Lancet , vol.353 , pp. 2001-2007
  • 26
    • 0035818884 scopus 로고    scopus 로고
    • A randomized trial of the angiotensin-receptor blocker val-sartan in chronic heart failure.
    • Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker val-sartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
    • (2001) N Engl J Med , vol.345 , pp. 1667-1675
    • Cohn, J.N.1    Tognoni, G.2
  • 27
    • 0033517302 scopus 로고    scopus 로고
    • Randomized Aldactone Evaluation Study Investigators. the effect of spironolac-tone on morbidity and mortality in patients with severe heart failure.
    • Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolac-tone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-717.
    • (1999) N Engl J Med , vol.341 , pp. 709-717
    • Pitt, B.1    Zannad, F.2    Remme, W.J.3    Cody, R.4    Castaigne, A.5    Perez, A.6    Palensky, J.7    Wittes, J.8
  • 28
    • 0042410539 scopus 로고    scopus 로고
    • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme
    • DOI 10.1016/S0140-6736(03)14282-1
    • Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766. (Pubitemid 37093915)
    • (2003) Lancet , vol.362 , Issue.9386 , pp. 759-766
    • Pfeffer, M.A.1    Swedberg, K.2    Granger, C.B.3    Held, P.4    McMurray, J.J.V.5    Michelson, E.L.6    Olofsson, B.7    Ostergren, J.8    Yusuf, S.9
  • 29
    • 31644432097 scopus 로고    scopus 로고
    • Chronic kidney disease in patients with cardiac disease: A review of evidence-based treatment.
    • McMurray JJ. Chronic kidney disease in patients with cardiac disease: a review of evidence-based treatment. Kidney Int 2005;68:1419-1426.
    • (2005) Kidney Int , vol.68 , pp. 1419-1426
    • McMurray, J.J.1
  • 30
    • 0036176161 scopus 로고    scopus 로고
    • K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification.
    • K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(Suppl. 2 1):S1-S266.
    • (2002) Am J Kidney Dis , vol.39 , Issue.SUPPL. 2 1
  • 32
    • 33646345152 scopus 로고    scopus 로고
    • KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease.
    • KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl. 5 3):S11-S145.
    • (2006) Am J Kidney Dis , vol.47 , Issue.SUPPL. 5 3
  • 34
    • 0041976976 scopus 로고    scopus 로고
    • Breast cancer trial with erythropoietin terminated unexpectedly
    • DOI 10.1016/S1470-2045(03)01163-X
    • Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460. (Pubitemid 37009952)
    • (2003) Lancet Oncology , vol.4 , Issue.8 , pp. 459-460
    • Leyland-Jones, B.1
  • 36
    • 0032572913 scopus 로고    scopus 로고
    • The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    • Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
    • (1998) N Engl J Med , vol.339 , pp. 584-590
    • Besarab, A.1    Bolton, W.K.2    Browne, J.K.3    Egrie, J.C.4    Nissenson, A.R.5    Okamoto, D.M.6    Schwab, S.J.7    Goodkin, D.A.8
  • 37
    • 33846682340 scopus 로고    scopus 로고
    • Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR.
    • Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007;22:309-312.
    • (2007) Nephrol Dial Transplant , vol.22 , pp. 309-312
    • Levin, A.1
  • 40
    • 71049154040 scopus 로고    scopus 로고
    • Amgen Inc. Aranespw (darbepoetin alfa). For injection. Last accessed on 17 September, 2009
    • Amgen Inc. Aranespw (darbepoetin alfa). For injection. http://www.aranesp.com/professional/crf/full-prescribing-info/pi.jsp. Last accessed on 17 September, 2009.
  • 41
    • 71049167851 scopus 로고    scopus 로고
    • Summary of Product Characteristics, Last accessed on 17 September, 2009
    • ARANESPw (darbepoetin alfa). Summary of Product Characteristics, 2008. http://www.amgen.co.uk/pdfs/Aranesp-PFS-SPC-Feb-08.pdf. Last accessed on 17 September, 2009.
    • (2008) ARANESPw (Darbepoetin Alfa)
  • 42
    • 33847785149 scopus 로고    scopus 로고
    • Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.
    • Van Veldhuisen DJ, McMurray JJ. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 2007;9:110-112.
    • (2007) Eur J Heart Fail , vol.9 , pp. 110-112
    • Van Veldhuisen, D.J.1    McMurray, J.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.